Optimization of Ganciclovir use in allogeneic hematopoietic cell transplant recipients – the role of therapeutic drug monitoring

References

• Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest. 2011 May;121(5):1673–1680.
   PubMed Web of Science ®Google Scholar
• Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection [review]. Rev Med Virol. 2010 Jul;20(4):202–213.
   PubMed Web of Science ®Google Scholar
• Chawla JS, Ghobadi A, Mosley III J, et al. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. Transplant Infect Dis. 2012;14(3):259–267.
   PubMed Web of Science ®Google Scholar
• Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study [Journal]. Lancet Haematol. 2016;3(3):e119–e127.
   PubMed Web of Science ®Google Scholar
• Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433.
   PubMed Web of Science ®Google Scholar
• de la Camara R. CMV in haematopoietic stem cell transplantation. Mediterr J Hematol Infect Dis. 2016;8:1.
   Web of Science ®Google Scholar
• Safdar A, Armstrong D. Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. Clinl Infect Dis. 2011;53(8):798–806.
   PubMed Web of Science ®Google Scholar
• Buhles WC. Compassionate use: a story of ethics and science in the development of a new drug. Perspect Biol Med. 2011;54(3):304–315.
   PubMed Web of Science ®Google Scholar
• Collaborative DTSG. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N Engl J Med. 1986 Mar 27;314(13):801–805.
   PubMed Web of Science ®Google Scholar
• Boeckh M. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy. Transplant Infect Dis. 1999 Sep 01;1(3):165–178.
   PubMedGoogle Scholar
• Ljungman P, de la Camara R, Robin C, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(8):e260–e272.
   PubMed Web of Science ®Google Scholar
• Erice A, Jordan MC, Chace BA, et al. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA. 1987;257(22):3082–3087.
   PubMed Web of Science ®Google Scholar
• Einsele H, Ljungman P, Boeckh M. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. Blood. 2020 May 7;135(19):1619–1629.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009 Jun 4;113(23):5711–5719.
   PubMed Web of Science ®Google Scholar
• Chen K, Cheng MP, Hammond SP, et al. Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation. Blood Adv. 2018 Aug 28;2(16):2159–2175.
   PubMed Web of Science ®Google Scholar
• Erard V, Guthrie KA, Seo S, et al. Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices. Clin Infect Dis. 2015 Jul 1;61(1):31–39.
   PubMed Web of Science ®Google Scholar
• Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007;7(9):2106–2113.
   PubMed Web of Science ®Google Scholar
• Ozkocaman V, Ozkalemkas F, Ali R, et al. Oral valganciclovir as preemptive therapy for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Blood. 2014;124(21):5855.
   Web of Science ®Google Scholar
• van der Heiden PL, Kalpoe JS, Barge RM, et al. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant. 2006 Apr;37(7):693–698.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Baden LR, Gabriel DA, et al. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biol Blood Marrow Transplant. 2006 Jun;12(6):635–640.
   PubMed Web of Science ®Google Scholar
• Crumpacker CS. Ganciclovir. N Engl J Med. 1996 Sep 5;335(10):721–729.
   PubMed Web of Science ®Google Scholar
• McNicholl IR, Jacobson MA, et al. Ganciclovir and valganciclovir. In: Grayson ML, Crowe SM, editors. Kucers’ the use of antibiotics sixth edition: a clinical review of antibacterial, antifungal and antiviral Drugs. London, United Kingdom: CRC Press; 2010.p. 2379–2393
   Google Scholar
• Biron KK, Stanat SC, Sorrell JB, et al. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci U S A. 1985 Apr;82(8):2473–2477.
   PubMed Web of Science ®Google Scholar
• Matthews T, Boehme R. Antiviral Activity and mechanism of action of ganciclovir. Rev Infect Dis. 1988;10:S490–S494.
   PubMedGoogle Scholar
• Scott JC, Partovi N, Ensom MHH. Ganciclovir in solid organ transplant recipients: is there a role for clinical pharmacokinetic monitoring? Ther Drug Monit. 2004;26(1):68–77.
   PubMed Web of Science ®Google Scholar
• Bean B. Antiviral therapy: current concepts and practices. Clin Microbiol Rev. 1992 Apr;5(2):146–182.
   PubMed Web of Science ®Google Scholar
• Mar EC, Cheng YC, Huang ES. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 1983;24(4):518–521.
   PubMed Web of Science ®Google Scholar
• Rose J, Emery VC, Kumar D, et al. Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection. PLoS Pathog. 2017 Apr;13(4):e1006299.
   PubMed Web of Science ®Google Scholar
• Smee DF, Martin JC, Verheyden JP, et al. Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Antimicrob Agents Chemother. 1983;23(5):676.
   PubMed Web of Science ®Google Scholar
• Schmidt S, Barbour A, Sahre M, et al. PK/PD: new insights for antibacterial and antiviral applications. Curr Opin Pharmacol. 2008 Oct;8(5):549–556.
   PubMed Web of Science ®Google Scholar
• Fishman JA, Doran MT, Volpicelli SA, et al. Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients. Transplantation. 2000;69(3):389–394.
   PubMed Web of Science ®Google Scholar
• Fletcher C, Sawchuk R, Chinnock B, et al. Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther. 1986;40(3):281–286.
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Drew WL, Felsenstein D, et al. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J Infect Dis. 1985;152(4):833–834.
   PubMed Web of Science ®Google Scholar
• Landry ML, Stanat S, Biron K, et al. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother. 2000;44(3):688–692.
   PubMed Web of Science ®Google Scholar
• Cvetkovic RS, Wellington K. Valganciclovir. Drugs. 2005 April 01;65(6):859–878.
   PubMed Web of Science ®Google Scholar
• Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation. 2005 Jun 15;79(11):1477–1483.
   PubMed Web of Science ®Google Scholar
• Perrottet N, Decosterd LA, Meylan P, et al. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements [journal article]. Clin Pharmacokinet. 2009 June 01;48(6):399–418.
   PubMed Web of Science ®Google Scholar
• Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 1990;39(4):597–638.
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother. 2000 Oct;44(10):2811–2815.
   PubMed Web of Science ®Google Scholar
• Einsele H, Reusser P, Bornhäuser M, et al. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood. 2006;107(7):3002–3008.
   PubMed Web of Science ®Google Scholar
• Lim ZY, Cook G, Johnson PR, et al. Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation. Leuk Res. 2009 Feb;33(2):244–249.
   PubMed Web of Science ®Google Scholar
• Manuel O, Perrottet N, Pascual M. Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation. Expert Rev Anti Infect Ther. 2011 Nov 01;9(11):955–965.
   PubMed Web of Science ®Google Scholar
• Markham A, Faulds D. ganciclovir an update of its therapeutic use in cytomegalovirus infection [journal article]. Drugs. 1994 September 01;48(3):455–484.
   PubMed Web of Science ®Google Scholar
• Czock D, Scholle C, Rasche FM, et al. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther. 2002 Aug 01;72(2):142–150.
   PubMed Web of Science ®Google Scholar
• Sommadossi J-P, Rae B, Teck L, et al. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev Infect Dis. 1988;10:S507–S514.
   PubMedGoogle Scholar
• Venton G, Crocchiolo R, Fürst S, et al. Risk factors of Ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients. Clin Microbiol Infect. 2014 Feb 01;20(2):160–166.
   PubMed Web of Science ®Google Scholar
• Sommadossi J-P, Carlisle R. Toxicity of 3?-azido-3?-deoxy- thymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for nor- malhuman hematopoietic progenitor cells in vitro. Antimicrob Agent Chemother. 1987;31(3):452–454.
   PubMed Web of Science ®Google Scholar
• Snoeck R, Lagneaux L, Delforge A, et al. Inhibitory effects of potent inhibitors of human immunodeficiency virus and cytomegalovirus on the growth of human granulocyte-macrophage progenitor cells in vitro. Eur J Clin Microbiol Infect Dis. 1990 Aug;9(8):615–619.
   PubMed Web of Science ®Google Scholar
• Takahata M, Hashino S, Nishio M, et al. Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration. Transplant Infect Dis. 2015 Dec 01;17(6):810–815.
   PubMed Web of Science ®Google Scholar
• Buhles WC Jr., Mastre RJ, Tinker AJ, et al. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Clinl Infect Dis. 1988;10(Supplement_3):S495–S506.
   Google Scholar
• Reed EC, Shepp DH, Dandliker PS, et al. Ganciclovir treatment of cytomegalovirus infection of the gastrointestinal tract after marrow transplantation. Bone Marrow Transplant. 1988 May;3(3):199–206.
   PubMed Web of Science ®Google Scholar
• Shepp DH, Dandliker PS, de Miranda P, et al. Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med. 1985 Sep;103(3):368–373.
   PubMed Web of Science ®Google Scholar
• Kanda Y, Mineishi S, Saito T, et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant. 2001 Feb;27(4):437–444.
   PubMed Web of Science ®Google Scholar
• Billat P-A, Woillard J-B, Essig M, et al. Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity? J Antimicrob Chemother. 2015;71(2):484–489.
   PubMed Web of Science ®Google Scholar
• Ritchie BM, Barreto JN, Barreto EF, et al. Relationship of ganciclovir therapeutic drug monitoring with clinical efficacy and patient safety. Antimicrob Agents Chemother. 2019 Mar;63(3):e01855–18
   PubMed Web of Science ®Google Scholar
• Perrottet N, Manuel O, Lamoth F, et al. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients. BMC Infect Dis. 2010;10(1):2.
   PubMedGoogle Scholar
• Gimenez E, Solano C, Azanza JR, et al. Monitoring of trough plasma ganciclovir levels and peripheral blood cytomegalovirus (CMV)-specific CD8+ T cells to predict CMV DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients. Antimicrob Agents Chemother. 2014 Sep;58(9):5602–5605.
   PubMed Web of Science ®Google Scholar
• Spector SA, Busch DF, Follansbee S, et al. Pharmacokinetic, safety, and antiviral profiles of oral Ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. J Infect Dis. 1995;171(6):1431–1437.
   PubMed Web of Science ®Google Scholar
• Piketty C, Bardin C, Gilquin J, et al. Low plasma concentrations achieved with conventional schedules administration of ganciclovir in patients with AIDS [article]. J Infect Dis. 1996 Jul;174(1):188–190.
   PubMed Web of Science ®Google Scholar
• Piketty C, Bardin C, Gilquin J, et al. Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis [Article]. Clin Microbiol Infect. 2000;6(3):117–120.
   PubMed Web of Science ®Google Scholar
• Bedino G, Esposito P, Bosio F, et al. The role of therapeutic drug monitoring in the treatment of cytomegalovirus disease in kidney transplantation [article]. Int Urol Nephrol. 2013 Dec;45(6):1809–1813.
   PubMed Web of Science ®Google Scholar
• Luck S, Lovering A, Griffiths P, et al. Ganciclovir treatment in children: evidence of subtherapeutic levels. Int J Antimicrob Agents. 2011 May;37(5):445–448.
   PubMed Web of Science ®Google Scholar
• Esposito P, Bedino G, Montagna F, et al. Ganciclovir-resistant cytomegalovirus infection in transplanted patients: utility of drug monitoring. Transplant Infect Dis. 2013;15(3):E122–E123.
   PubMed Web of Science ®Google Scholar
• Laskin OL, Stahl-Bayliss CM, Kalman CM, et al. Use of Ganciclovir to treat serious cytomegalovirus infections in patients with AIDS. J Infect Dis. 1987;155(2):323–327.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir therapy for cytomegalovirus infections in recipients of bone marrow transplants and other immunosuppressed patients. Rev Infect Dis. 1988 Jul-Aug;10(S3):S547–53
   Google Scholar
• Trevillyan J, Angus P, Shelton E, et al. Electronic estimations of renal function are inaccurate in solid-organ transplant recipients and can result in significant underdosing of prophylactic valganciclovir. Antimicrob Agents Chemother. 2013 Aug;57(8):4058–4060.
   PubMed Web of Science ®Google Scholar
• Lefeuvre S, Chevalier P, Charpentier C, et al. Valganciclovir prophylaxis for cytomegalovirus infection in thoracic transplant patients: retrospective study of efficacy, safety, and drug exposure. Transpl Infect Dis. 2010 Jun;12(3):213–219.
   PubMed Web of Science ®Google Scholar
• Welker H, Farhan M, Humar A, et al. Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days. Transplantation. 2010;90(12):1414–1419.
   PubMed Web of Science ®Google Scholar
• Valganciclovir [Internet]. CRC Press Taylor & Francis Group. 2019 [cited 2019 Nov 11]. Available from: https://renaldrugdatabase.com/monographs/valganciclovir.
   Google Scholar
• Ganciclovir [Internet]. CRC Press Taylor & Francis Group. 2019 [cited 2019 Nov 11]. Available from: https://renaldrugdatabase.com/monographs/ganciclovir.
   Google Scholar
• Valcyte [Internet]. MIMS Online. 2002 [cited 2019 Nov 11]. Available from: https://www-mimsonline-com-au-acs-hcn-com-au.ezp.lib.unimelb.edu.au/Search/FullPI.aspx?ModuleName=Product%20Info&searchKeyword=valganciclovir&PreviousPage=~/Search/QuickSearch.aspx&SearchType=&ID=64140001_2.
   Google Scholar
• Cymevene [Internet]. Mims Online. 1991 [cited 2019 Nov 11]. Available from: https://www-mimsonline-com-au-acs-hcn-com-au.ezp.lib.unimelb.edu.au/Search/FullPI.aspx?ModuleName=Product%20Info&searchKeyword=ganciclovir&PreviousPage=~/Search/QuickSearch.aspx&SearchType=&ID=9820001_2.
   Google Scholar
• Asano-Mori Y, Kanda Y, Oshima K, et al. Pharmacokinetics of ganciclovir in haematopoietic stem cell transplantation recipients with or without renal impairment. J Antimicrob Chemother. 2006 May;57(5):1004–1007.
   PubMed Web of Science ®Google Scholar
• Traynor J, Mactier R, Geddes CC, et al. How to measure renal function in clinical practice. BMJ. 2006 Oct 7;333(7571):733–737.
   PubMed Web of Science ®Google Scholar
• Trevisani F, Di Marco F, Capitanio U, et al. Renal function assessment gap in clinical practice: an awkward truth. Kidney Blood Press Res. 2020;45(2):166–179.
   PubMed Web of Science ®Google Scholar
• Posadas Salas MA, Taber DJ, Chua E, et al. Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation. Transpl Infect Dis. 2013 Dec;15(6):551–558.
   PubMed Web of Science ®Google Scholar
• Echenique IA, Beltran D, Ramirez-Ruiz L, et al. Ganciclovir dosing strategies and development of cytomegalovirus resistance in a kidney transplant recipient: a case report. Transplant Proc. 2017 sep 01;49(7):1560–1564.
   PubMed Web of Science ®Google Scholar
• Stockmann C, Roberts JK, Knackstedt ED, et al. Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection. Expert Opin Drug Metab Toxicol. 2015 Feb 01;11(2):205–219.
   PubMed Web of Science ®Google Scholar
• Krens SD, Hodiamont CJ, Juffermans NP, et al. Population pharmacokinetics of Ganciclovir in critically Ill patients. Ther Drug Monit. 2019 Aug 16;42(2):295–301
   Web of Science ®Google Scholar
• Horvatits T, Kitzberger R, Drolz A, et al. Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically Ill patients. Antimicrob Agents Chemother. 2014;58(1):94.
   PubMed Web of Science ®Google Scholar
• Bastien O, Boulieu R, Bleyzac N, et al. Clinical use of ganciclovir during renal failure and continuous hemodialysis. Intensive Care Med. 1994 Jan 01;20(1):47–48.
   PubMed Web of Science ®Google Scholar
• Zhang D, Lapeyraque AL, Popon M, et al. Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. Pediatr Nephrol. 2003 Sep;18(9):943–948.
   PubMed Web of Science ®Google Scholar
• Vethamuthu J, Feber J, Chretien A, et al. Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children. Pediatr Transplant. 2007 May;11(3):301–305.
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Ettenger RB, Strife CF, et al. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients. Transpl Infect Dis. 2010 Jun;12(3):195–203.
   PubMed Web of Science ®Google Scholar
• Asberg A, Bjerre A, Neely M. New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients. Pediatr Transplant. 2014 Feb;18(1):103–111.
   PubMed Web of Science ®Google Scholar
• Villeneuve D, Brothers A, Harvey E, et al. Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients. Pediatr Transplant. 2013 Feb;17(1):80–85.
   PubMed Web of Science ®Google Scholar
• Jorga K, Reigner B, Chavanne C, et al. Pediatric dosing of ganciclovir and valganciclovir: how model-based simulations can prevent underexposure and potential treatment failure. CPT Pharmacometrics Syst Pharmacol. 2019 Mar;8(3):167–176.
   PubMedGoogle Scholar
• Lalezari JP, Friedberg DN, Bissett J, et al. High dose oral ganciclovir treatment for cytomegalovirus retinitis. J Clin Virol. 2002 Feb;24(1–2):67–77.
   PubMed Web of Science ®Google Scholar
• Jung D, Griffy K, Wong R, et al. Steady-state relative bioavailability of three oral ganciclovir dosage regimens delivering 6,000 mg/day in patients with human immunodeficiency virus. J Clin Pharmacol. 1998;38:1021–1024
   PubMed Web of Science ®Google Scholar
• Vethamuthu J, Feber J, Chretien A, et al. Unexpectedly high inter- and intrapatient variability of Ganciclovir levels in children. Pediatr Transplant. 2007;11(3):301–305.
   PubMed Web of Science ®Google Scholar
• Wiltshire H, Hirankarn S, Farrell C, et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients [journal article]. Clin Pharmacokinet. 2005 May 01;44(5):495–507.
   PubMed Web of Science ®Google Scholar
• Linard J, Knutson C, Wells R, et al. Does the use of serum ganciclovir levels to adjust valganciclovir dosing prevent the development of CMV Resistance in CMV mismatched heart transplant recipients? The Mid America experience [meeting abstract]. J Heart Lung Transplant. 2019 Apr;38(4):S119–S119.
   Web of Science ®Google Scholar
• Tängdén T, Cojutti PG, Roberts JA, et al. Valganciclovir pharmacokinetics in patients receiving oral prophylaxis following kidney transplantation and model-based predictions of optimal dosing regimens [journal article]. Clin Pharmacokinet. 2018 November 01;57(11):1399–1405.
   PubMed Web of Science ®Google Scholar
• Padulles A, Colom H, Bestard O, et al. Contribution of population pharmacokinetics to dose optimization of ganciclovir-valganciclovir in solid-organ transplant patients. Antimicrob Agents Chemother. 2016 Apr;60(4):1992–2002.
   PubMed Web of Science ®Google Scholar
• Jorga K, Chavanne C, Frey N, et al. Bottom-up meets top-down: complementary physiologically based pharmacokinetic and population pharmacokinetic modeling for regulatory approval of a dosing algorithm of valganciclovir in very young children. Clin Pharmacol Ther. 2016 Dec;100(6):761–769.
   PubMed Web of Science ®Google Scholar
• Drew WL. Cytomegalovirus resistance testing: pitfalls and problems for the clinician. Clinl Infect Dis. 2010;50(5):733–736.
   PubMed Web of Science ®Google Scholar
• Stern L, Withers B, Avdic S, et al. Human cytomegalovirus latency and reactivation in allogeneic hematopoietic stem cell transplant recipients. Front Microbiol. 2019;10:1186.
   PubMed Web of Science ®Google Scholar
• Emery VC, Hassan-Walker AF, Burroughs AK, et al. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. J Infect Dis. 2002 Jun 15;185(12):1723–1728.
   PubMed Web of Science ®Google Scholar
• D’Souza A, Fretham C. Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR summary slides, 2018. 2018.
   Google Scholar
• Kotton CN, Kumar D, Caliendo AM, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. 2018. p. 900–931.
   Google Scholar
• Jung S, Michel M, Stamminger T, et al. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient. BMC Infect Dis. 2019 May 08;19(1):388.
   PubMedGoogle Scholar
• Cherrier L, Nasar A, Goodlet KJ, et al. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. Am J Transplant. 2018 Dec;18(12):3060–3064.
   PubMed Web of Science ®Google Scholar